MoVo-guided Traditional Chinese Kegel Exercises for Preventing Postpartum Urinary Incontinence.
A Prospective Randomized Controlled Trial of MoVo-guided Liuzijue Combined With Traditional Levator Ani Exercise During Pregnancy for Preventing Postpartum Urinary Incontinence.
The goal of this clinical trial is to determine whether a prenatal exercise program integrating Liuzijue qigong with traditional levator ani training, guided by the MoVo (Motivation-Volition) theory and delivered via a supervised mobile application, can effectively prevent postpartum urinary incontinence and pelvic organ prolapse in pregnant women, compared with app-supervised conventional Kegel exercises and routine prenatal care.
The main questions it aims to answer are:
Does the integrated Liuzijue-and-levator-ani program reduce the incidence of postpartum urinary incontinence and prolapse more effectively than app-supervised Kegel exercises or routine care?
Can the MoVo-based behavioural framework (motivation enhancement, action planning, and self-monitoring) improve long-term adherence to pelvic floor training during pregnancy and the postpartum period?
What are the effects of the three interventions on pelvic floor muscle function, exercise self-efficacy, anxiety levels, and delivery outcomes?
Researchers will compare three parallel groups: (1) the integrated Liuzijue-and-levator-ani exercise group, (2) the app-supervised conventional Kegel exercise group, and (3) the routine care control group receiving only verbal instruction on pelvic floor exercises during standard prenatal visits. All three groups will be followed from enrolment through 6 weeks postpartum to determine whether the culturally adapted mind-body intervention offers superior pelvic floor protection beyond app-delivered Kegel training and routine care.
Participants will:
Be enrolled in the third trimester and randomly assigned to one of the three groups.
In the integrated exercise group, perform daily combined Liuzijue-and-levator-ani exercises via a supervised mobile app and attend periodic check-ins until 6 weeks postpartum.
In the app-supervised Kegel group, perform daily conventional Kegel exercises via the same mobile app platform with the same supervision schedule.
In the routine care group, receive only standard verbal instructions on Kegel exercises during regular antenatal check-ups, without app supervision.
Undergo outcome evaluations at enrolment, before delivery, and at the postpartum follow-up visit, including assessments of urinary incontinence, pelvic organ prolapse, exercise adherence, self-efficacy, anxiety, and any adverse events.
Visão geral do estudo
Status
Condições
Tipo de estudo
Inscrição (Estimado)
Estágio
- Não aplicável
Contactos e Locais
Contato de estudo
- Nome: Yuxin Y Qian
- Número de telefone: +8613247548104
- E-mail: 2710559471@qq.com
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
- Adulto
Aceita Voluntários Saudáveis
Descrição
Inclusion Criteria:
- Age ≥ 19 years
- Singleton pregnancy with cephalic presentation；
- No absolute contraindications to vaginal delivery；
- No history of urinary incontinence, pelvic organ prolapse, or pelvic floor surgery before pregnancy；
- Ability and willingness to comply with the full prenatal and postpartum follow-up schedule；
- Signed written informed consent.
Exclusion Criteria:
- History of second- or third-trimester miscarriage, recurrent miscarriage, or spontaneous preterm birth；
- Presence of pregnancy complications, such as severe preeclampsia, fetal distress, placenta previa, placental abruption, or symptoms of threatened preterm labour；
- Contraindications to exercise, including cervical shortening, cervical insufficiency, or unexplained vaginal bleeding or fluid leakage；
- Comorbid conditions, such as asthma, cardiovascular disease, hypertension, uncontrolled diabetes mellitus, or thyroid disease；
- Metabolic bone disease or limited joint mobility；
- Cognitive or psychiatric disorders that prevent the participant from completing diary records；
- Concurrent participation in another pelvic floor intervention study.
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Prevenção
- Alocação: Randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Solteiro
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Comparador de Placebo: control group
Routine prenatal care with only verbal instructions on Kegel exercises (no app, no supervision).
|
Routine prenatal care with only verbal instructions on Kegel exercises (no app, no supervision)
|
|
Experimental: App-Kegel group
App-supervised daily conventional Kegel exercises (same platform, no Liuzijue/MoVo).
|
App-supervised daily conventional Kegel exercises (same platform, no Liuzijue/MoVo).
|
|
Experimental: TCM comprehensive group
App-supervised daily Liuzijue combined with levator ani training, guided by MoVo theory.
|
App-supervised daily Liuzijue combined with levator ani training, guided by MoVo theory.
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Proportion of participants with urinary incontinence at 42 days postpartum, assessed by the International Consultation on Incontinence Questionnaire - Urinary Incontinence Short Form (ICIQ-UI SF)
Prazo: 42 days postpartum
|
The ICIQ-UI SF is a validated, self-administered questionnaire that evaluates the frequency, volume, and impact of urinary incontinence (UI) over the previous 4 weeks.
Total scores range from 0 to 21, with higher scores indicating more severe symptoms.
This outcome is defined as the proportion of participants reporting any urine leakage (score ≥1) on the ICIQ-UI SF at the 42-day postpartum follow-up.
The chi-square test will be used to compare the incidence of urinary incontinence between the intervention and control groups.
|
42 days postpartum
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Adherence to the antenatal exercise intervention, assessed by exercise diary completion rate
Prazo: at 3 months post-intervention
|
Adherence is evaluated by two combined measures: (1) exercise diary completion rate = (actual number of training sets completed / planned number of training sets) × 100%; and (2) the proportion of participants who perform active training on at least 4 days per week, with each training day defined as completing at least 50% of the planned sets.
The mean adherence rate and the proportion of adherent participants will be reported for the intervention group.
|
at 3 months post-intervention
|
|
Pelvic floor muscle strength assessed by the Modified Oxford Grading Scale.
Prazo: 42 days postpartum
|
The Modified Oxford Grading Scale evaluates pelvic floor muscle contraction strength via vaginal palpation, with grades ranging from 0 (no contraction) to 5 (strong contraction).
Median and interquartile range will be reported for each group, and the Mann-Whitney U test will be used for comparison.
|
42 days postpartum
|
|
Change in self-efficacy for pelvic floor exercises, assessed by the Pelvic Floor Exercise Self-Efficacy Scale
Prazo: Enrolment, 37 weeks of gestation, 42 days postpartum
|
The Pelvic Floor Exercise Self-Efficacy Scale is a validated self-report instrument that measures the participant's confidence in adhering to pelvic floor exercise.
Total scores range from 0 to 100, with higher scores indicating greater self-efficacy.
Assessments will be performed at three time points: enrolment, 37 weeks of gestation, and 42 days postpartum.
Mean ± standard deviation of scores and change from baseline will be reported for each group.
Repeated-measures analysis of variance (ANOVA) will be used to compare differences between groups.
|
Enrolment, 37 weeks of gestation, 42 days postpartum
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Investigador principal: ming M Yang, Guangzhou University of Chinese Medicine
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Estimado)
Conclusão Primária (Estimado)
Conclusão do estudo (Estimado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Termos MeSH relevantes adicionais
- Doenças urogenitais
- Doenças Urogenitais Masculinas
- Doenças Urológicas
- Doenças Urogenitais Femininas
- Doenças urogenitais femininas e complicações na gravidez
- Distúrbios da micção
- Sintomas do Trato Urinário Inferior
- Manifestações Urológicas
- Incontinencia urinaria
- Condições Patológicas, Sinais e Sintomas
- Sinais e sintomas
- Incontinência Urinária, Estresse
Outros números de identificação do estudo
- GDSHLXHYJYB202608
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .